Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of dupilumab for itch in adults with lichen simplex chronicus
CTR20244736Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of dupilumab in neurodermatitis, sponsored by Sanofi. Started Jan 2025; status: completed.
02
Drugs
03
Conditions
neurodermatitis
Beyond the preview
Go deeper on CTR20244736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244736.